Adalimumab biosimilar FKB327 causes less pain than originator

Posted 09/04/2021

Fujifilm Kyowa Kirin Biologics’ adalimumab biosimilar FKB327 has been found to cause less injection-site pain compared to the reference product, according to...

New partnerships for Cipla and Samsung Bioepis Pharma News | Posted 09/04/2021
Biosimilars regulation, clinical trials, approv... Biosimilars/Research | Posted 09/04/2021
FDA accepts application for adalimumab biosimil... Biosimilars/News | Posted 09/04/2021
Biosimilars of ustekinumab Biosimilars/General | Posted 09/04/2021
Dispensing branded drugs costs Medicare over a... Generics/Research | Posted 09/04/2021
China improves generics injection consistency e... Policies & Legislation | Posted 09/04/2021
Etanercept biosimilar injection pen, YLB113, co... Biosimilars/Research | Posted 02/04/2021
Technological approaches to drug repurposing fo... Generics/Research | Posted 02/04/2021
Samsung Bioepis and Eden Biologics announce new... Biosimilars/Research | Posted 02/04/2021
Australian and Indian approval for teriparatide... Biosimilars/News | Posted 02/04/2021
Biosimilars of aflibercept Biosimilars/General | Posted 02/04/2021
EMA recommends approval of abiraterone and thio... Generics/News | Posted 02/04/2021
Biosimilars in Europe: prescriber survey Biosimilars/Research | Posted 26/03/2021
Argentina approves bevacizumab similar biologic... Biosimilars/News | Posted 26/03/2021
EC approval for insulin aspart biosimilar Kixelle Biosimilars/News | Posted 26/03/2021
Public health impact of using biosimilars and r... Biosimilars/Research | Posted 26/03/2021
Italy simplifies over-the-counter generics pric... Policies & Legislation | Posted 26/03/2021
Teva and Sandoz launch new generics Generics/News | Posted 26/03/2021
Pelmeg developed with aid of regulatory reform Biosimilars/Research | Posted 19/03/2021
IVM releases toolbox on how to switch patients... Biosimilars/General | Posted 19/03/2021
EMA recommends approval of fourth COVID-19 vaccine Generics/News | Posted 19/03/2021
Knowledge and perceptions about naming biosimil... Biosimilars/Research | Posted 19/03/2021
Debate about generic versus brand-name drugs fo... Generics/Research | Posted 19/03/2021
EC approves adalimumab biosimilar Yuflyma Biosimilars/News | Posted 19/03/2021
Approaches to naming and labelling of biosimilars Biosimilars/Research | Posted 12/03/2021
EMA recommends approval of four bevacizumab bio... Biosimilars/News | Posted 12/03/2021
Australia launches new medicines road map and s... Policies & Legislation | Posted 12/03/2021
China accepts IND application for daratumumab c... Biosimilars/News | Posted 12/03/2021
Infliximab biosimilars for IBD patients: experi... Biosimilars/Research | Posted 12/03/2021
Posaconazole, silodosin and droxidopa generics... Generics/News | Posted 12/03/2021
Different approaches to the interchangeability... Biosimilars/Research | Posted 05/03/2021
Latest launches for adalimumab biosimilars in C... Biosimilars/News | Posted 05/03/2021
Biosimilar patent litigation trends in the US Biosimilars/General | Posted 05/03/2021
Efficacy and safety of interferon beta-1a (Reci... Biosimilars/Research | Posted 05/03/2021
The role of authorized generics in improving ac... Generics/Research | Posted 05/03/2021
Opportunities for generics with Korean patent e... Generics/General | Posted 05/03/2021
Access! AAM Annual Meeting 2021 Conferences | Posted 05/03/2021
Collaboration between regulatory authorities fo... Biosimilars/Research | Posted 26/02/2021


FDA issues final guidance on liposome drug products Posted 27/04/2018

On 4 April 2018, the US Food and Drug Administration (FDA) issued a new draft...


FDA approves 40 mg follow-on version of glatira... Non‐Biological Complex Drugs/News | Posted 09/03/2018
Mylan launches first follow-on glatiramer aceta... Non‐Biological Complex Drugs/News | Posted 15/02/2018
Biosimilars and follow-on NBCDs for MS in Europ... Non‐Biological Complex Drugs/Research | Posted 19/01/2018
Impax announces FDA approval of follow-on sevel... Non‐Biological Complex Drugs/News | Posted 17/11/2017
FDA approves follow-on version of sevelamer Non‐Biological Complex Drugs/News | Posted 30/06/2017
Challenges in the regulation of NBCDs Non‐Biological Complex Drugs/Research | Posted 12/05/2017
Scientific and regulatory considerations for fo... Non‐Biological Complex Drugs/Research | Posted 04/05/2017
Equivalence of complex drug products Non‐Biological Complex Drugs/Reports | Posted 14/04/2017
Follow-up studies needed to ensure safety for f... Non‐Biological Complex Drugs/Research | Posted 31/03/2017
Warning letter causes delays for follow-on glat... Non‐Biological Complex Drugs/News | Posted 17/03/2017
Is the EU ready for non-biological complex drug... Non‐Biological Complex Drugs/Research | Posted 03/03/2017
Follow-on versions of glatiramer acetate in Rus... Non‐Biological Complex Drugs/News | Posted 24/02/2017
Non-biological complex drugs and pharmacopoeias Non‐Biological Complex Drugs/Research | Posted 10/02/2017
In vitro analysis of follow-on versions of seve... Non‐Biological Complex Drugs/Research | Posted 18/11/2016
Determining the bioequivalence of follow-on iro... Non‐Biological Complex Drugs/Reports | Posted 04/11/2016
FDA to set up abbreviated pathway for complex p... Non‐Biological Complex Drugs/Polices & Legislation | Posted 21/10/2016
Challenges in the assessment of ophthalmic emul... Non‐Biological Complex Drugs/Reports | Posted 07/10/2016
Cancer lab to evaluate bioequivalence of nanosi... Non‐Biological Complex Drugs/News | Posted 23/09/2016
A conference on ‘Equivalence of Complex Drug Pr... Non‐Biological Complex Drugs/News | Posted 09/09/2016
Collaboration to introduce nanotechnologies in... Non‐Biological Complex Drugs/News | Posted 26/08/2016
Iron carbohydrate follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 12/08/2016
Rigorous approach used to approve a follow-on v... Non‐Biological Complex Drugs/Research | Posted 29/07/2016
US guidelines for follow-on NBCDs Non‐Biological Complex Drugs/Guidelines | Posted 10/06/2016
Non-biological complex drugs and their follow-o... Non‐Biological Complex Drugs/Research | Posted 03/06/2016
Is a new pathway for NBCDs on the way in the US? Non‐Biological Complex Drugs/Polices & Legislation | Posted 27/05/2016
Follow-on glatiramer acetate gains European app... Non‐Biological Complex Drugs/News | Posted 13/05/2016
FDA includes follow-on versions in its new cycl... Non‐Biological Complex Drugs/Guidelines | Posted 29/04/2016
Switching between originator and follow-on iron... Non‐Biological Complex Drugs/Research | Posted 22/04/2016
Follow-on intravenous iron formulations in haem... Non‐Biological Complex Drugs/Research | Posted 01/04/2016
Glatiramoid follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 11/03/2016
FDA includes follow-on versions in its new lipo... Non‐Biological Complex Drugs/Guidelines | Posted 26/02/2016
EU guidelines for follow-on NBCDs Non‐Biological Complex Drugs/Guidelines | Posted 22/01/2016
GDUFA regulatory priorities for 2016 include co... Non‐Biological Complex Drugs/Polices & Legislation | Posted 11/12/2015
Liposomal follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 11/12/2015
Regulations for follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 13/11/2015
Status and regulatory issues surrounding follow... Non‐Biological Complex Drugs/Reports | Posted 05/11/2015
Follow-on glatiramer acetate (M356) claimed as... Non‐Biological Complex Drugs/Research | Posted 05/11/2015
EMA issues reflection paper for follow-on versi... Non‐Biological Complex Drugs/Guidelines | Posted 05/11/2015
FDA approves first follow-on version of glatira... Non‐Biological Complex Drugs/News | Posted 05/11/2015

Generics News Research General


Biosimilars News Research General